CTNNA3

CTNNA3 Full Name

catenin (cadherin-associated protein), alpha 3

CTNNA3 Introduction

CTNNA3 (also known as alpha-T-catenin or alpha-catenin-like protein 1) is a member of the catenin family of proteins that play essential roles in cell-cell adhesion by linking cadherin adhesion receptors to the actin cytoskeleton. Unlike the ubiquitously expressed CTNNA1 (alpha-E-catenin) and the neuronally enriched CTNNA2 (alpha-N-catenin), CTNNA3 exhibits a more restricted expression pattern, with highest levels in the heart, testis, and brain, as well as in various epithelial tissues. The protein functions as a key component of the adherens junction complex, where it binds directly to beta-catenin or gamma-catenin (plakoglobin), which in turn bind to the cytoplasmic tail of classical cadherins. Through this interaction, CTNNA3 anchors the cadherin-catenin complex to the actin filament network, providing mechanical stability to cell-cell junctions and transducing signals that regulate cell proliferation, differentiation, and migration. CTNNA3 has also been identified as a putative tumor suppressor gene, with frequent inactivation by promoter hypermethylation or deletion in various human cancers, including prostate cancer, breast cancer, and lung cancer.

Figure 1. Schematic structure of CTNNA3.

Role as a Tumor Suppressor in Cancer
CTNNA3 is increasingly recognized as a tumor suppressor gene that is frequently inactivated in various human malignancies. Promoter hypermethylation of CTNNA3 has been detected in prostate cancer, breast cancer, non-small cell lung cancer, esophageal squamous cell carcinoma, gastric cancer, colorectal cancer, hepatocellular carcinoma, and cervical cancer, and this hypermethylation correlates with reduced or absent CTNNA3 expression. Loss of CTNNA3 expression promotes cancer progression through multiple mechanisms. First, it destabilizes adherens junctions, reducing cell-cell adhesion and facilitating tumor cell detachment, invasion, and metastasis. Second, loss of CTNNA3 derepresses epithelial-mesenchymal transition (EMT), leading to downregulation of E-cadherin and upregulation of mesenchymal markers such as vimentin and N-cadherin. Third, CTNNA3 loss activates pro-invasive signaling pathways including Wnt/beta-catenin and TGF-beta signaling, which promote tumor progression. Fourth, CTNNA3 deficiency disrupts contact inhibition, allowing uncontrolled proliferation. In prostate cancer, CTNNA3 methylation is an early event detected in high-grade prostatic intraepithelial neoplasia (HGPIN) and increases with tumor grade and stage, and it is associated with biochemical recurrence after radical prostatectomy. In breast cancer, CTNNA3 methylation correlates with aggressive phenotypes including triple-negative subtype and poor patient survival.

Clinical Significance and Therapeutic Implications
The frequent inactivation of CTNNA3 in human cancers has significant clinical implications. Methylation of the CTNNA3 promoter has been proposed as a diagnostic and prognostic biomarker for several cancer types. In prostate cancer, CTNNA3 methylation in urine or biopsy samples can distinguish cancer from benign tissue with high specificity, and it predicts disease recurrence and progression. In non-small cell lung cancer, CTNNA3 methylation correlates with lymph node metastasis and poor prognosis. In breast cancer, CTNNA3 expression status may predict response to chemotherapy, with loss of expression conferring resistance to certain agents. Beyond cancer, CTNNA3 mutations have been identified in patients with congenital heart disease and arrhythmogenic cardiomyopathy. Genetic variants in CTNNA3 have also been associated with atrial fibrillation and other cardiac arrhythmias in genome-wide association studies. Therapeutically, restoring CTNNA3 expression using DNA methyltransferase inhibitors such as decitabine or azacitidine could re-establish cell-cell adhesion and suppress tumor progression. Additionally, CTNNA3 expression status may guide the use of EMT-targeting therapies, including inhibitors of TGF-beta signaling and HDAC inhibitors. Preclinical studies suggest that CTNNA3 restoration sensitizes cancer cells to conventional chemotherapy and targeted agents, opening avenues for combination therapy.

Alternate Names for CTNNA3

CTNNA3; catenin (cadherin-associated protein), alpha 3; catenin alpha-3; MGC26194; VR22; alpha T-catenin; alpha-T-catenin; alpha-catenin-like protein; cadherin-associated protein; MGC75041;